Recent Advances in Imaging of Dopaminergic Neurons for Evaluation of Neuropsychiatric Disorders

Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory. To date, there are numerous positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers available for targeting different steps in the process of dopaminergic neurotransmission, which permits us to quantify dopaminergic activity in the living human brain. Degeneration of the nigrostriatal dopamine system causes Parkinson's disease (PD) and related Parkinsonism. Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. Abnormalities within the dopamine system in the brain are involved in the pathophysiology of attention deficit hyperactivity disorder (ADHD). Dopamine receptors play an important role in schizophrenia and the effect of neuroleptics is through blockage of dopamine D2 receptors. This review will concentrate on the radiotracers that have been developed for imaging dopaminergic neurons, describe the clinical aspects in the assessment of neuropsychiatric disorders, and suggest future directions in the diagnosis and management of such disorders.

• Publication year

  2012

• Venue

  Journal of Biomedicine and Biotechnology

• Publication date

  2012-04-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2012/259349PMID 22570524PMCID 3335602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 1 – Radioactivity, Radionuclides, and Radiopharmaceuticals

  2012cited by this paper
• The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.

  2011influential reference
• Gene therapy: a viable therapeutic strategy for Parkinson’s disease?

  2011cited by this paper
• Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia

  2011cited by this paper
• In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

  2011cited by this paper
• ATP13A2 variability in Taiwanese Parkinson's disease

  2011cited by this paper
• Availability of dopamine and serotonin transporters in opioid-dependent users—a two-isotope SPECT study

  2011cited by this paper
• Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes

  2010cited by this paper
• The application of PET technique for the development and evaluation of novel antipsychotics.

  2010cited by this paper
• Brain receptor imaging.

  2010cited by this paper
• Positron Emission Tomography in Schizophrenia: A New Perspective

  2010cited by this paper
• Recent advances in PET imaging for evaluation of Parkinson’s disease

  2010influential reference
• Whole-Body Biodistribution and Radiation Dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): A Novel Vesicular Monoamine Transporter 2 Imaging Agent

  2010cited by this paper
• A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

  2010cited by this paper
• Imaging for early differential diagnosis of parkinsonism.

  2010cited by this paper
• Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines.

  2010cited by this paper
• In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133

  2010cited by this paper
• Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy

  2010influential reference
• Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy

  2009cited by this paper
• Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

  2009cited by this paper
• Imaging neurodegeneration in Parkinson's disease.

  2009cited by this paper
• Neuroprotection and imaging studies in Parkinson's disease.

  2009cited by this paper
• Molecular Imaging Studies in Parkinson Disease: Reducing Diagnostic Uncertainty

  2009cited by this paper
• Molecular Imaging

  2009cited by this paper
• Imaging dopamine's role in drug abuse and addiction.

  2009cited by this paper
• Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder.

  2009cited by this paper
• Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study.

  2008cited by this paper
• PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.

  2008cited by this paper
• SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder

  2008cited by this paper
• Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes

  2008cited by this paper
• Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

  2008cited by this paper
• Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

  2008cited by this paper
• Dopamine transporter levels in cocaine dependent subjects.

  2008cited by this paper
• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

  2008cited by this paper
• Dopamine Transporter Binding in Smokers and Nonsmokers

  2007cited by this paper
• Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait

  2007cited by this paper
• PINK1 mutation in Taiwanese early-onset parkinsonism

  2007cited by this paper
• Brain imaging research: Does the science serve clinical practice?

  2007cited by this paper
• Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

  2007cited by this paper
• Epidepride binding to cerebellar dopamine D 2 / D 3 receptors is displaceable : Implications for the use of cerebellum as a reference region

  2007cited by this paper
• Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders

  2007influential reference
• [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region

  2007cited by this paper
• Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.

  2007cited by this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cited by this paper
• PINK1 mutation in Taiwanese early-onset parkinsonism : clinical, genetic, and dopamine transporter studies.

  2007cited by this paper
• The diagnosis of Parkinson's disease.

  2006cited by this paper
• Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder

  2006cited by this paper
• Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder

  2006cited by this paper
• Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

  2005cited by this paper
• In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter.

  2005cited by this paper
• Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease

  2005cited by this paper
• Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD

  2005cited by this paper
• The role of radiotracer imaging in Parkinson disease.

  2005cited by this paper
• The role of radiotracer imaging in Parkinson disease.

  2005cited by this paper
• Vascular parkinsonism--an important cause of parkinsonism in older people.

  2005influential reference
• 99mTc-TRODAT-1 imaging of multiple system atrophy.

  2004cited by this paper
• Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET

  2004cited by this paper
• IBZM-SPECT imaging of dopamine D 2 receptors with typical and atypical antipsychotics

  2004cited by this paper
• The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.

  2004cited by this paper
• Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

  2004cited by this paper
• Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects.

  2004cited by this paper
• Functional Imaging in Parkinson’s Disease and Dementia with Lewy Bodies

  2004cited by this paper
• Do we still believe in the dopamine hypothesis? New data bring new evidence.

  2004cited by this paper
• Dopamine in drug abuse and addiction: results from imaging studies and treatment implications

  2004cited by this paper
• The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder.

  2003cited by this paper
• Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

  2003influential reference
• The diagnosis of Parkinson's disease.

  2003cited by this paper
• Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder.

  2003cited by this paper
• Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.

  2003cited by this paper
• 99m Tc-TRODAT-1 Imaging of Multiple System Atrophy

  2003cited by this paper
• Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder

  2003cited by this paper
• Crossover Study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson’s Disease Patients

  2003cited by this paper
• Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).

  2003cited by this paper
• Imaging studies in movement disorders.

  2003cited by this paper
• Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications

  2002cited by this paper
• Neuropsychopharmacology : The Fifth Generation of Progress

  2002cited by this paper
• PET and SPET tracers for mapping the cardiac nervous system

  2002cited by this paper
• Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease.

  2002cited by this paper
• Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia

  2002cited by this paper
• Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol

  2002cited by this paper
• Normal dopamine transporter binding in dopa responsive dystonia

  2002influential reference
• PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.

  2002cited by this paper
• Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder.

  2002cited by this paper
• Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers.

  2002influential reference
• Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder.

  2002cited by this paper
• Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain

  2001cited by this paper
• Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1.

  2001cited by this paper
• Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study

  2001cited by this paper
• Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?

  2001cited by this paper
• The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism

  2001cited by this paper
• Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging.

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• Molecular imaging.

  2001cited by this paper
• [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.

  2001cited by this paper
• Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

  2001cited by this paper
• MRI identification of early white matter injury in anoxic–ischemic encephalopathy

  2001cited by this paper
• Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex.

  2001cited by this paper
• [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease

  2001cited by this paper
• Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment

  2000cited by this paper
• Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group

  2000cited by this paper

• Acupuncture for Mild Cognitive Impairment in Vascular Parkinsonism: A Prospective, Randomized, Controlled Trial Protocol.

  2026cites this paper
• Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model

  2025cites this paper
• An appraisal on biomolecular imaging in diagnosis of neurological disorders and innovation in clinical research

  2025cites this paper
• Systematic Approach in the Development of Chitosan Functionalized Iloperidone Nanoemulsions for Transnasal Delivery, In Vitro and In Vivo Studies

  2024cites this paper
• THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.

  2024cites this paper
• MicroRNA dysregulation in glutamate and dopamine pathways of schizophrenia: From molecular pathways to diagnostic and therapeutic approaches.

  2024cites this paper
• A connectome-based model of delusion in schizophrenia using functional connectivity under working memory task.

  2024cites this paper
• Pathogenesis of depression and the potential for traditional Chinese medicine treatment

  2024cites this paper
• Increased NLRP1 mRNA and Protein Expression Suggests Inflammasome Activation in the Dorsolateral Prefrontal and Medial Orbitofrontal Cortex in Schizophrenia

  2024cites this paper
• Downregulation of miR-29a as a possible diagnostic biomarker for schizophrenia

  2024cites this paper
• Common and divergent neuroimaging features in major depression, posttraumatic stress disorder, and their comorbidity

  2024cites this paper
• Dopaminergic Epistases in Schizophrenia

  2024cites this paper
• Dopaminergic Modulation of Prefrontal Cortex Inhibition

  2023cites this paper
• A comprehensive update on genetic inheritance, epigenetic factors, associated pathology, and recent therapeutic intervention by gene therapy in schizophrenia

  2023cites this paper
• Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials

  2023cites this paper
• Downregulation of microRNA‐330‐5p induces manic‐like behaviors in REM sleep‐deprived rats by enhancing tyrosine hydroxylase expression

  2023cites this paper
• Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

  2022cites this paper
• The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health

  2022cites this paper
• Maternal immune activation leads to atypical turning asymmetry and reduced DRD2 mRNA expression in a rat model of schizophrenia.

  2021cites this paper
• Decreased Brain pH and Pathophysiology in Schizophrenia

  2021influential citation
• Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics

  2021cites this paper
• Pathogenesis of cerebral toxocariasis and neurodegenerative diseases.

  2020cites this paper
• Bacterial Metabolites of Human Gut Microbiota Correlating with Depression

  2020cites this paper
• Modulation of CNS Functions by Deep Brain Stimulation: Insights Provided by Molecular Imaging

  2020cites this paper
• Correlation between urinary incontinence and psychosis in patients with advanced‐stage Parkinson’s disease

  2020cites this paper
• Role of Neurochemicals in Schizophrenia

  2020cites this paper
• Molecular Biological Aspects of Depressive Disorders: A Modern View

  2020cites this paper
• Early Life Stress- and Drug-Induced Histone Modifications Within the Ventral Tegmental Area

  2020cites this paper
• Progress in the Study of Imaging Biomarkers of Parkinson’s Disease with REM Sleep Behaviour Disorder

  2020influential citation
• Positron emission computed tomography/single photon emission computed tomography in Parkinson disease

  2020cites this paper
• Perturbations in the catecholamine metabolism and protective effect of “3-(3, 4-dimethoxy phenyl)-1-4(methoxy phenyl) prop-2-en-1-one” during ketamine-induced schizophrenia: an in vivo and in silico studies

  2020cites this paper
• Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view.

  2020cites this paper
• Feasibility study of a point‐of‐care positron emission tomography system with interactive imaging capability

  2019cites this paper
• Comparative Study of Two Oxidizing Agents, Chloramine T and Iodo-Gen®, for the Radiolabeling of β-CIT with Iodine-131: Relevance for Parkinson’s Disease

  2019cites this paper
• Automatic Versus Semi-Automatic method for the striatum specific uptake ratio quantification based on [123I]FP-CIT SPECT images

  2019cites this paper
• Neurochemical evidence that cysteamine modulates amphetamine-induced dopaminergic neuronal activity in striatum by decreasing dopamine release: an in vivo microdialysis study in freely moving rats.

  2019cites this paper
• Actigraphic Screening for Rapid Eye Movement Sleep Behavior Disorder

  2019cites this paper
• Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience

  2019cites this paper
• Late onset depression: Association with clinical and imaging indicators of prodromal Parkinson’s disease

  2019cites this paper
• Changing Landscapes in the Neuroimaging of Dementia

  2018cites this paper
• Degree of dopaminergic degeneration measured by 99mTc-TRODAT-1 SPECT/CT imaging

  2018cites this paper
• Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson’s Disease and Other Synucleinopathies

  2018cites this paper
• Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases

  2017cites this paper
• Obtention de cellules souches humaines induites à la pluripotence à partir de cellules d'urine et leur différenciation neuronale

  2017cites this paper
• News and views on in-vivo imaging of neurotransmission using PET and MRI.

  2017cites this paper
• Automated Immunohistochemical Analysis of the Orbitofrontal Cortex in Patients with Schizophrenia, Bipolar Disorder and Major Depressive Disorder

  2017cites this paper
• Positron Emission Tomography Radiochemistry: Improved Methodology and a Novel PET Imaging Agent for the Dopamine D3 Receptor

  2017cites this paper
• Characterization of the effect of dopamine on the neural coding of reward-based learning and decision-making

  2017cites this paper
• Brain imaging and networks in restless legs syndrome.

  2017cites this paper
• Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - A systematic review on potential biomarkers for neurodegeneration.

  2017cites this paper
• The functional roles of T-cadherin in mammalian biology

  2017cites this paper
• The Effects of Varenicline on Neurocognitive Function in Non-smokers with Schizophrenia

  2016cites this paper
• Dopamine mediated modulation of electrotactic swimming behaviour in Caenorhabditis elegans

  2016cites this paper
• Braim imaging biomaker normalization, analysis and classification methods to characterize the progression of neurodegenerative diseases

  2016cites this paper
• Schizophrenia: Understanding the Madness

  2016cites this paper
• On the Complexity of Brain Disorders: A Symptom-Based Approach

  2016cites this paper
• Innovation of Neuropsychopharmacological Experimental Methods to Investigate Attention in Human Participants and Its Validation by Randomized Double Blind Placebo Controlled Clinical Trial

  2016cites this paper
• Fluorodopa is a Promising Fluorine‐19 MRI Probe for Evaluating Striatal Dopaminergic Function in a Rat Model of Parkinson's Disease

  2016cites this paper
• Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer

  2016cites this paper
• Reduction of dopamine in basal ganglia and its effects on syllable sequencing in speech: A computer simulation study

  2016influential citation
• Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

  2015cites this paper
• Role of Hybrid Brain Imaging in Neuropsychiatric Disorders

  2015cites this paper
• Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.

  2015cites this paper
• Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study

  2015cites this paper
• Association between phthalates and attention deficit disorder and learning disability in U.S. children, 6-15 years.

  2014cites this paper
• In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

  2014cites this paper
• Dopamine D1- and D2-Receptors in Immunostimulation under Activation of Mu-Opioid Receptors in Mice with Different Psychoemotional States

  2014cites this paper
• Effects of glutathione S-transferase M1 and T1 deletions on epilepsy risk among a Tunisian population.

  2014cites this paper
• Brain circuit model for drug addiction

  2014cites this paper
• The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue

  2014cites this paper
• Neuroimaging of Delirium

  2014cites this paper
• Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders.

  2014cites this paper
• Stress-mediated modulations in dopaminergic system and their subsequent impact on behavioral and oxidative alterations: An update

  2014cites this paper
• Title Stuttering candidate genes DRD 2 but not SLC 6 A 3 is associatedwith developmental dyslexia in Chinese population

  2014cites this paper
• SPECT Imaging for Idiopatic M. Parkinson and Parkinsonian Syndromes: Guidelines and Comparison with PET and Recent Developments

  2014cites this paper
• Stuttering candidate genes DRD2 but not SLC6A3 is associated with developmental dyslexia in Chinese population

  2014cites this paper
• Association between Attention-Deficit Hyperactivity Disorder in childhood and schizophrenia later in adulthood

  2014cites this paper
• Radioiodination of Zaleplon and Its in-vivo Biologic Behavior in Mice: An Imaging Probe for Brain

  2013cites this paper
• Amelioration of Behavioral Abnormalities in BH4-deficient Mice by Dietary Supplementation of Tyrosine

  2013cites this paper
• Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease

  2013cites this paper
• Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeys

  2013cites this paper
• The Endocannabinoid Antagonist AM251 as a Method of Protection Prior to Global Cerebral Ischemia: Implications for Dopamine Function, Neuronal Survival and Behaviour

  2013cites this paper
• Cognitive dysfunctions in recreational and dependent cocaine users: role of attention-deficit hyperactivity disorder, craving and early age at onset

  2013cites this paper
• Biomarkers in Parkinson's disease (recent update).

  2013cites this paper
• A New Perspective on Temperamental Shyness: Differential Susceptibility to Endoenvironmental Influences

  2013cites this paper
• Studies of GluN2C-containing NMDA receptors in schizophrenia-like behaviors and fear learning; Relevance to the glutamate hypofunction hypothesis of schizophrenia

  2012cites this paper
• Does baseline cerebral blood flow affect task-related blood oxygenation level dependent response in schizophrenia?

  2012cites this paper
• Central Dopaminergic System and Its Implications in Stress-Mediated Neurological Disorders and Gastric Ulcers: Short Review

  2012cites this paper